Characterizing the Safety and Efficacy of Propofol in Critically Ill Pediatric Patients
The Journal of Pediatric Pharmacology and Therapeutics · 2026-08 · 31 (4) · 540-548
DOI: 10.5863/jppt-25-00063 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pediatric Pharmacology and Therapeutics, 2026-08. Verfasst von Benjamin Colwell und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy (BC, FB, MS, JT, AAS), NYU Langone Medical Center. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
OBJECTIVES Propofol is used sparingly in pediatrics owing to the risk of propofol-related infusion syndrome (PRIS). The objective of this study is to evaluate the safety of propofol in pediatrics and describe its effectiveness at facilitating extubation and decreasing concomitant sedation. METHODS This retrospective, descriptive study evaluated critically ill children who received continuous propofol infusions for at least 12 consecutive hours while admitted to pediatric, congenital cardiac, or neonatal intensive care units. The primary outcome was PRIS incidence. Secondary outcomes included change from baseline in laboratory parameters, discontinuation due to adverse effects, change in sedative requirements following sedation washout, and successful extubation. RESULTS From January 1, 2019, to November 1, 2023, a total of 100 children received 120 courses of propofol infusions. The median infusion rate was 106 mcg/kg/min (IQR, 68–149) and 27.5% of courses exceeded 48 hours in duration. No PRIS events were identified. Patients experienced a moderate, non–duration-dependent increase in triglycerides, with no impact on aspartate aminotransferase (AST)/alanine aminotransferase (ALT) concentrations; 11.7% of infusions were discontinued for adverse effects. No children self-extubated while on propofol when used for peri-extubation (N = 49). Opioid and benzodiazepine requirements were decreased by 17% and 26% from baseline, respectively, during a 24-hour period following sedation washout (N = 26). CONCLUSIONS Propofol was tolerated by most patients at doses commonly exceeding guideline-recommended maximum rate and duration. Propofol was safely used to facilitate extubation and decreased baseline sedative exposure when used for sedation washout in a complex critically ill pediatric population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy (BC, FB, MS, JT, AAS), NYU Langone Medical Center.
- Department of Pediatrics (AJS), NYU Langone Medical Center, New York, NY.
Zitieren
APA
Colwell, B., Bashqoy, F., Spilios, M., Tracy, J., Shah, A. J., & Saad, A. A. (2026). Characterizing the Safety and Efficacy of Propofol in Critically Ill Pediatric Patients. The Journal of Pediatric Pharmacology and Therapeutics, 31(4), 540-548. https://doi.org/10.5863/jppt-25-00063
Vancouver
Colwell B, Bashqoy F, Spilios M, Tracy J, Shah AJ, Saad AA. Characterizing the Safety and Efficacy of Propofol in Critically Ill Pediatric Patients. The Journal of Pediatric Pharmacology and Therapeutics. 2026;31(4):540-548. doi:10.5863/jppt-25-00063
BibTeX
@article{Colwell2026,
author = {Colwell, Benjamin and Bashqoy, Ferras and Spilios, Maria and Tracy, Joanna and Shah, Ami J and Saad, Anasemon A},
title = {Characterizing the Safety and Efficacy of Propofol in Critically Ill Pediatric Patients},
journal = {The Journal of Pediatric Pharmacology and Therapeutics},
year = {2026},
volume = {31},
number = {4},
pages = {540--548},
doi = {10.5863/jppt-25-00063}
}
EUVIMED